This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Todd L. Maus, MD; Lill-Inger Larsson, MD; Jay W. McLaren, PhD; Richard F. Brubaker, MD

Arch Ophthalmol. 1997;115(1):45-49.

Abstract
Objective
To compare the efficacy of topical 2% dorzolamide hydrochloride (Trusopt) as a suppressor of aqueous humor flow in the human eye with the efficacy of systemically administered acetazolamide (Diamox).

Design
A randomized, double-masked, placebo-controlled study of 40 human subjects in 2 academic centers. The effect of dorzolamide on aqueous humor flow was compared with that of acetazolamide as measured by the rate of clearance of topically applied fluorescein.

Results
Acetazolamide reduced aqueous flow from 3.18±0.70 (mean±SD) to 2.23±0.48 µL per minute, a reduction of 30% (P<.001), and dorzolamide reduced the flow to 2.65±0.64 µL per minute, a reduction of 17% (P<.001). The difference between the effect of acetazolamine and dorzolamide was significant (P<.001). When acetazolamide is added to dorzolamide, the aqueous flow was reduced further to 2.21±0.47 µL per minute, an additional reduction of 16% (P<.001). When dorzolamide was added to acetazolamide, no additional reduction was observed (P=.73). Similar effects were observed for intraocular pressure. Acetazolamide reduced pressure from 12.5±2.2 (mean±SD) to 10.1±2.2 mm Hg, a decrease of 19% (P<.001) and dorzolamide reduced it to 10.8±2.1 mm Hg, or a decrease of 13% (P<.001). The greater effect of acetazolamide than dorzolamide was significant (P=.03).

Conclusions
For reasons that are not known, the topically applied carbonic anhydrase inhibitor 2% dorzolamide hydrochloride is not as effective as systemically administered acetazolamide. Clinicians who prescribe dorzolamide should expect less of an ocular hypotensive effect than that experienced from systemically administered acetazolamide.

Author Affiliations
From the Departments of Ophthalmology, Mayo Clinic, Rochester, Minn (Drs Maus, McLaren, and Brubaker), and Uppsala University, Uppsala, Sweden (Dr Larsson). The authors have no financial interest in any of the materials mentioned in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Aqueous Humor Flow in Normal Human Eyes Treated With Brimonidine and Dorzolamide, Alone and in Combination
Tsukamoto and Larsson
Arch Ophthalmol 2004;122:190-193.
ABSTRACT | FULL TEXT  

A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study
O'Donoghue and the UK and Ireland Latanoprost Study Group
Br J Ophthalmol 2000;84:579-582.
ABSTRACT | FULL TEXT  

Comparison of the Early Effects of Brimonidine and Apraclonidine as Topical Ocular Hypotensive Agents
Maus et al.
Arch Ophthalmol 1999;117:586-591.
ABSTRACT | FULL TEXT  

Additive Effect of Dorzolamide on Aqueous Humor Flow in Patients Receiving Long-term Treatment With Timolol
Wayman et al.
Arch Ophthalmol 1998;116:1438-1440.
ABSTRACT | FULL TEXT  

Aqueous Humor Flow in Human Eyes Treated With Dorzolamide and Different Doses of Acetazolamide
Larsson and Alm
Arch Ophthalmol 1998;116:19-24.
ABSTRACT | FULL TEXT  

Comparison of Dorzolamide and Timolol as Suppressors of Aqueous Humor Flow in Humans
Wayman et al.
Arch Ophthalmol 1997;115:1368-1371.
ABSTRACT